1083 related articles for article (PubMed ID: 28902593)
1. Patent Foramen Ovale Closure or Anticoagulation vs. Antiplatelets after Stroke.
Mas JL; Derumeaux G; Guillon B; Massardier E; Hosseini H; Mechtouff L; Arquizan C; Béjot Y; Vuillier F; Detante O; Guidoux C; Canaple S; Vaduva C; Dequatre-Ponchelle N; Sibon I; Garnier P; Ferrier A; Timsit S; Robinet-Borgomano E; Sablot D; Lacour JC; Zuber M; Favrole P; Pinel JF; Apoil M; Reiner P; Lefebvre C; Guérin P; Piot C; Rossi R; Dubois-Randé JL; Eicher JC; Meneveau N; Lusson JR; Bertrand B; Schleich JM; Godart F; Thambo JB; Leborgne L; Michel P; Pierard L; Turc G; Barthelet M; Charles-Nelson A; Weimar C; Moulin T; Juliard JM; Chatellier G;
N Engl J Med; 2017 Sep; 377(11):1011-1021. PubMed ID: 28902593
[TBL] [Abstract][Full Text] [Related]
2. Patent Foramen Ovale Closure or Antiplatelet Therapy for Cryptogenic Stroke.
Søndergaard L; Kasner SE; Rhodes JF; Andersen G; Iversen HK; Nielsen-Kudsk JE; Settergren M; Sjöstrand C; Roine RO; Hildick-Smith D; Spence JD; Thomassen L;
N Engl J Med; 2017 Sep; 377(11):1033-1042. PubMed ID: 28902580
[TBL] [Abstract][Full Text] [Related]
3. Long-Term Outcomes of Patent Foramen Ovale Closure or Medical Therapy after Stroke.
Saver JL; Carroll JD; Thaler DE; Smalling RW; MacDonald LA; Marks DS; Tirschwell DL;
N Engl J Med; 2017 Sep; 377(11):1022-1032. PubMed ID: 28902590
[TBL] [Abstract][Full Text] [Related]
4. The Case for Selective Patent Foramen Ovale Closure After Cryptogenic Stroke.
Wiktor DM; Carroll JD
Circ Cardiovasc Interv; 2018 Mar; 11(3):e004152. PubMed ID: 29870380
[TBL] [Abstract][Full Text] [Related]
5. Closure, Anticoagulation, or Antiplatelet Therapy for Cryptogenic Stroke With Patent Foramen Ovale: Systematic Review of Randomized Trials, Sequential Meta-Analysis, and New Insights From the CLOSE Study.
Turc G; Calvet D; Guérin P; Sroussi M; Chatellier G; Mas JL;
J Am Heart Assoc; 2018 Jun; 7(12):. PubMed ID: 29910193
[TBL] [Abstract][Full Text] [Related]
6. close: Closure of patent foramen ovale, oral anticoagulants or antiplatelet therapy to prevent stroke recurrence: Study design.
Mas JL; Derumeaux G; Amarenco P; Arquizan C; Aubry P; Barthelet M; Bertrand B; Brochet E; Cabanes L; Donal E; Dubois-Randé JL; Durand-Zaleski I; Ernande L; Finet G; Fraisse A; Giroud M; Guérin P; Habib G; Juliard JM; Leys D; Lièvre M; Lusson JR; Marcon F; Michel P; Moulin T; Mounier-Vehier F; Pierard L; Piot C; Rey C; Rodier G; Roudaut R; Schleich JM; Teiger E; Turc G; Vuillier F; Weimar C; Woimant F; Chatellier G;
Int J Stroke; 2016 Aug; 11(6):724-32. PubMed ID: 27056964
[TBL] [Abstract][Full Text] [Related]
7. Patent foramen ovale closure, antiplatelet therapy or anticoagulation in patients with patent foramen ovale and cryptogenic stroke: a systematic review and network meta-analysis incorporating complementary external evidence.
Mir H; Siemieniuk RAC; Ge L; Foroutan F; Fralick M; Syed T; Lopes LC; Kuijpers T; Mas JL; Vandvik PO; Agoritsas T; Guyatt GH
BMJ Open; 2018 Jul; 8(7):e023761. PubMed ID: 30049703
[TBL] [Abstract][Full Text] [Related]
8. Patent foramen ovale closure with GORE HELEX or CARDIOFORM Septal Occluder vs. antiplatelet therapy for reduction of recurrent stroke or new brain infarct in patients with prior cryptogenic stroke: Design of the randomized Gore REDUCE Clinical Study.
Kasner SE; Thomassen L; Søndergaard L; Rhodes JF; Larsen CC; Jacobson J
Int J Stroke; 2017 Dec; 12(9):998-1004. PubMed ID: 29090661
[TBL] [Abstract][Full Text] [Related]
9. Patent foramen ovale transcatheter closure vs. medical therapy on recurrent vascular events: a systematic review and meta-analysis of randomized controlled trials.
Rengifo-Moreno P; Palacios IF; Junpaparp P; Witzke CF; Morris DL; Romero-Corral A
Eur Heart J; 2013 Nov; 34(43):3342-52. PubMed ID: 23847132
[TBL] [Abstract][Full Text] [Related]
10. Closure versus medical therapy for preventing recurrent stroke in patients with patent foramen ovale and a history of cryptogenic stroke or transient ischemic attack.
Li J; Liu J; Liu M; Zhang S; Hao Z; Zhang J; Zhang C
Cochrane Database Syst Rev; 2015 Sep; 2015(9):CD009938. PubMed ID: 26346232
[TBL] [Abstract][Full Text] [Related]
11. Closure of patent foramen ovale versus medical therapy after cryptogenic stroke.
Carroll JD; Saver JL; Thaler DE; Smalling RW; Berry S; MacDonald LA; Marks DS; Tirschwell DL;
N Engl J Med; 2013 Mar; 368(12):1092-100. PubMed ID: 23514286
[TBL] [Abstract][Full Text] [Related]
12. Is Patent Foramen Ovale Closure More Effective Than Medical Therapy in Preventing Stroke Recurrence in Patients With Cryptogenic Stroke?: A Critically Appraised Topic.
Valencia-Sanchez C; Fortuin FD; Sweeney JP; Ingall TJ; Marks LA; Wingerchuk DM; O'Carroll CB
Neurologist; 2018 Sep; 23(5):175-180. PubMed ID: 30169372
[TBL] [Abstract][Full Text] [Related]
13. Percutaneous closure versus medical therapy alone for cryptogenic stroke patients with a patent foramen ovale: meta-analysis of randomized controlled trials.
Pickett CA; Villines TC; Ferguson MA; Hulten EA
Tex Heart Inst J; 2014 Aug; 41(4):357-67. PubMed ID: 25120387
[TBL] [Abstract][Full Text] [Related]
14. Predictors of recurrent events in patients with cryptogenic stroke and patent foramen ovale within the CLOSURE I (Evaluation of the STARFlex Septal Closure System in Patients With a Stroke and/or Transient Ischemic Attack Due to Presumed Paradoxical Embolism Through a Patent Foramen Ovale) trial.
Elmariah S; Furlan AJ; Reisman M; Burke D; Vardi M; Wimmer NJ; Ling S; Chen X; Kent DM; Massaro J; Mauri L;
JACC Cardiovasc Interv; 2014 Aug; 7(8):913-20. PubMed ID: 25147037
[TBL] [Abstract][Full Text] [Related]
15. A meta-analysis of transcatheter closure of patent foramen ovale versus medical therapy for prevention of recurrent thromboembolic events in patients with cryptogenic cerebrovascular events.
Pineda AM; Nascimento FO; Yang SC; Kirtane AJ; Sommer RJ; Beohar N
Catheter Cardiovasc Interv; 2013 Nov; 82(6):968-75. PubMed ID: 23832613
[TBL] [Abstract][Full Text] [Related]
16. Long-term outcomes of patent foramen ovale closure or medical therapy after cryptogenic stroke: A meta-analysis of randomized trials.
Abdelaziz HK; Saad M; Abuomara HZ; Nairooz R; Pothineni NVK; Madmani ME; Roberts DH; Mahmud E
Catheter Cardiovasc Interv; 2018 Jul; 92(1):176-186. PubMed ID: 29726616
[TBL] [Abstract][Full Text] [Related]
17. Percutaneous Closure of Patent Foramen Ovale in Patients with Cryptogenic Stroke - An Updated Comprehensive Meta-Analysis.
Sitwala P; Khalid MF; Khattak F; Bagai J; Bhogal S; Ladia V; Mukherjee D; Daggubati R; Paul TK
Cardiovasc Revasc Med; 2019 Aug; 20(8):687-694. PubMed ID: 30282597
[TBL] [Abstract][Full Text] [Related]
18. Percutaneous closure of patent foramen ovale in cryptogenic embolism.
Meier B; Kalesan B; Mattle HP; Khattab AA; Hildick-Smith D; Dudek D; Andersen G; Ibrahim R; Schuler G; Walton AS; Wahl A; Windecker S; Jüni P;
N Engl J Med; 2013 Mar; 368(12):1083-91. PubMed ID: 23514285
[TBL] [Abstract][Full Text] [Related]
19. Randomized clinical trial comparing percutaneous closure of patent foramen ovale (PFO) using the Amplatzer PFO Occluder with medical treatment in patients with cryptogenic embolism (PC-Trial): rationale and design.
Khattab AA; Windecker S; Jüni P; Hildick-Smith D; Dudek D; Andersen HR; Ibrahim R; Schuler G; Walton AS; Wahl A; Mattle HP; Meier B
Trials; 2011 Feb; 12():56. PubMed ID: 21356042
[TBL] [Abstract][Full Text] [Related]
20. Device closure of patent foramen ovale versus medical therapy in cryptogenic stroke: a systematic review and meta-analysis.
Khan AR; Bin Abdulhak AA; Sheikh MA; Khan S; Erwin PJ; Tleyjeh I; Khuder S; Eltahawy EA
JACC Cardiovasc Interv; 2013 Dec; 6(12):1316-23. PubMed ID: 24139929
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
